Coronary disease & ACSSecondary analysis
Abbreviated Dual Antiplatelet Therapy in Patients With High Bleeding Risk Undergoing Percutaneous Coronary Intervention (PCI) of Bifurcation Lesions: A Prespecified Substudy of the MASTER DAPT Trial
- Prespecified substudy of the MASTER DAPT trial
- randomized
Authors' conclusion
Among patients with high bleeding risk with or without bifurcation PCI, abbreviated DAPT was associated with lower bleeding risk without an excess of ischemic or net adverse events compared with standard DAPT.
Study context
- Population
- Patients with high bleeding risk who were free from ischemic or bleeding events after 1 month of PCI, with or without PCI of bifurcation lesionspatients randomized · bifurcation PCI 976 (21.2%)
- Participants
- 4,579 patients
- Comparison
- abbreviated DAPT vs standard DAPT
- Primary endpoint
- Coprimary outcomes: net adverse clinical outcomes events, major adverse cardiac and cerebral events, and BARC type 2, 3, or 5 bleeding
- Follow-up
- 335 days after randomization
Primary result
As reported in the abstract
abbreviated DAPT vs standard DAPTHazard ratio (95% CI)P value
Net adverse clinical event, patients with bifurcation PCI
0.98(0.73–1.17)
major adverse cardiac and cerebral events, patients with bifurcation PCI
0.92(0.63–1.54)
Net adverse clinical event, patients without bifurcation PCI
1.14(0.67–1.93)
P = 0.803for interactionmajor adverse cardiac and cerebral events, patients without bifurcation PCI
0.96(0.74–1.25)
P = 0.563for interactionBARC 2, 3, or 5 bleeding, patients with bifurcation
0.83(0.53–1.30)
BARC 2, 3, or 5 bleeding, patients without bifurcation
0.65(0.51–0.82)
P = 0.321for interactionOriginal publication
Abbreviated Dual Antiplatelet Therapy in Patients With High Bleeding Risk Undergoing PCI of Bifurcation Lesions: A Prespecified Substudy of the MASTER DAPT Trial. Circ Cardiovasc Interv. Published 13 July 2026. doi:10.1161/circinterventions.125.016222
Summarised from the published abstract; every number is checked against it